This study will examine the efficacy and safety of pegaptanib sodium in Japanese patients with wet-type AMD, in order to establish that there is no large difference in the efficacy and the safety of the drug between Western and Japanese patients.

Condition	Intervention	Phase
Macular Degeneration	Drug: pegaptanib sodium	Phase II

Further Study Details: 

Primary Outcomes: Visual aquity change from the baseline to 54 weeks after the first treatment is expected to be similar to that seen in the Western studies.
Secondary Outcomes: Safety profile of pegaptanib including side effects and lab test from the baseline to 54 weeks after the first treatment. Blood concentration of the drug from the baseline to 54 weeks after the irst treatment.
Expected Total Enrollment:  90

Ages Eligible for Study:  50 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

- Wet AMD, Visual Acuity from 20/320 to 20/40

Exclusion Criteria:

- Diabetic retinopathy, laser coagulation history

Please refer to this study by ClinicalTrials.gov identifier  NCT00150202

Pfizer CT.gov Call Center      1-800-718-1021 

Japan
      Pfizer Investigational Site, Fukushima,  960-1295,  Japan; Recruiting
      Pfizer Investigational Site, Kyoto,  606-8507,  Japan; Recruiting
Japan, Aichi
      Pfizer Investigational Site, Nagoya,  Aichi,  466-8560,  Japan; Recruiting
Japan, CHIBA-KEN
      Pfizer Investigational Site, Urayasu-shi,  CHIBA-KEN,  279-0021,  Japan; Recruiting
Japan, Chiyoda-ku
      Pfizer Investigational Site, Tokyo,  Chiyoda-ku,  Japan; Recruiting
Japan, Fukuoka-ken
      Pfizer Investigational Site, Fukuoka-shi,  Fukuoka-ken,  812-8582,  Japan; Recruiting
Japan, Gunma
      Pfizer Investigational Site, Maebashi,  Gunma,  371-8511,  Japan; Recruiting
Japan, Hokkaido
      Pfizer Investigational Site, Sapporo,  Hokkaido,  060-8604,  Japan; Recruiting
Japan, Kagawa
      Pfizer Investigational Site, Kida-gun,  Kagawa,  761-0793,  Japan; Recruiting
Japan, Osaka
      Pfizer Investigational Site, Suita,  Osaka,  565-0871,  Japan; Recruiting
      Pfizer Investigational Site, Moriguchi,  Osaka,  570-8506,  Japan; Recruiting
Japan, Shiga
      Pfizer Investigational Site, Otsu,  Shiga,  520-2192,  Japan; Recruiting
Japan, Tokyo
      Pfizer Investigational Site, Mitaka,  Tokyo,  181-8611,  Japan; Recruiting
      Pfizer Investigational Site, Shinjuku-ku,  Tokyo,  160-8582,  Japan; Recruiting

Study chairs or principal investigators

Pfizer CT.gov Call Center,  Study Director,  Pfizer   

Study ID Numbers:  A5751010
Last Updated:  September 7, 2005
Record first received:  September 6, 2005
ClinicalTrials.gov Identifier:  NCT00150202
Health Authority: Japan: Ministry of Health, Labor and Welfare
ClinicalTrials.gov processed this record on 2005-09-13